HEPION PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
HEPION PHARMACEUTICALS, INC. (HEPA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $87.12 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-03-12
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-12-31 was $62.18K, a 310.43% increase year-over-year.
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-09-30 was -$9.00.
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-06-30 was -$63.02K.
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-03-31 was $87.98K, a 354.60% increase year-over-year.
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $87.12K, a 664.98% increase from fiscal 2023.
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $11.39K.
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$90.17K.
- HEPION PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2021 was $0.00.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-12-31 | $62.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $62.17K derived: sum of 2 quarters · filed 2026-03-12 | -$855.00 derived: sum of 3 quarters · filed 2026-03-12 | $87.12K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$9.00 10-Q · filed 2025-11-12 | -$63.03K derived: sum of 2 quarters · filed 2025-11-12 | $24.95K 10-Q · filed 2025-11-12 | $40.10K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$63.02K 10-Q · filed 2025-11-12 | $24.96K 10-Q · filed 2025-08-14 | $40.11K derived: sum of 3 quarters · filed 2025-11-12 | $33.83K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | $87.98K 10-Q · filed 2025-11-12 | $103.13K derived: sum of 2 quarters · filed 2025-11-12 | $96.85K derived: sum of 3 quarters · filed 2025-11-12 | $80.02K derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | $15.15K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08 | $8.87K derived: sum of 2 quarters · filed 2025-04-08 | -$7.96K derived: sum of 3 quarters · filed 2025-04-08 | $11.39K 10-K · filed 2025-04-08 |
| 2023-09-30 | -$6.28K 10-Q · filed 2024-11-14 | -$23.11K derived: sum of 2 quarters · filed 2024-11-14 | -$3.76K 10-Q · filed 2024-11-14 | -$3.59K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$16.84K 10-Q · filed 2024-11-14 | $2.52K 10-Q · filed 2024-08-13 | $2.68K derived: sum of 3 quarters · filed 2024-11-14 | -$57.68K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-03-31 | $19.35K 10-Q · filed 2024-11-14 | $19.52K derived: sum of 2 quarters · filed 2024-11-14 | -$40.85K derived: sum of 3 quarters · filed 2024-11-14 | -$79.96K derived: sum of 4 quarters · filed 2024-11-14 |
| 2022-12-31 | $167.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$60.20K derived: sum of 2 quarters · filed 2024-04-16 | -$99.31K derived: sum of 3 quarters · filed 2024-04-16 | -$90.17K 10-K · filed 2024-04-16 |
| 2022-09-30 | -$60.37K 10-Q · filed 2023-11-20 | -$99.48K derived: sum of 2 quarters · filed 2023-11-20 | -$90.33K 10-Q · filed 2023-11-20 | -$90.33K derived: sum of 4 quarters · filed 2023-11-20 |
| 2022-06-30 | -$39.11K 10-Q · filed 2023-11-20 | -$29.97K 10-Q · filed 2023-08-14 | -$29.97K derived: sum of 3 quarters · filed 2023-11-20 | -$29.97K derived: sum of 4 quarters · filed 2023-11-20 |
| 2022-03-31 | $9.15K 10-Q · filed 2023-11-20 | $9.15K derived: sum of 2 quarters · filed 2023-11-20 | $9.15K derived: sum of 3 quarters · filed 2023-11-20 | $9.15K derived: sum of 4 quarters · filed 2023-11-20 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | $0.00 derived: sum of 2 quarters · filed 2023-04-10 | $0.00 derived: sum of 3 quarters · filed 2023-04-10 | $0.00 10-K · filed 2023-04-10 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |